Influence of hypertension on lower urinary tract symptoms in benign prostatic hyperplasia

International Journal of Urology

Volumn 10, Issue 11, 2003, Pages 569-574

  Sugaya, Kimio ^a   Kadekawa, Katsumi ^b   Ikehara, Akashi ^b   Nakayama, Tomoyuki ^b   Gakiya, Munehisa ^c   Nashiro, Fumio ^d   Goya, Masato ^a,e   Hatano, Tadashi ^a   Ogawa, Yoshihide ^a  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

^b Tomishiro Central Hospital   (Japan)

^c Okinawa Prefectural Miyako Hospital   (Japan)

^d National Okinawa Hospital   (Japan)

^e Department of Urology   (Japan)

Author keywords

Benign prostatic hyperplasia; Hypertension; International Prostate Symptom Score; Lower urinary tract symptoms; Terazosin

Indexed keywords

TERAZOSIN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; CALCULATION; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NOCTURIA; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; SCORING SYSTEM; SYMPTOM; SYSTOLIC BLOOD PRESSURE; URINARY FREQUENCY; UROFLOWMETRY;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; BLOOD PRESSURE; HUMANS; HYPERTENSION; MALE; PRAZOSIN; PROSTATIC HYPERPLASIA; REFERENCE VALUES; TREATMENT OUTCOME; URINATION DISORDERS;

EID: 0345167101     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-2042.2003.00707.x     Document Type: Article

References (21)

1. Lepor H. Natural history, evaluation, and nonsurgical management of benign prostatic hyperplasia. In: Walsh PC, Retik AB, Vaughan ED Jr, Wein AJ (eds). Campbell's Urology, 7th edn. WB Saunders, Philadelphia, 1998, 1453-77.
2. Yasuda K, Yamanishi T, Tojo M, Nagashima K, Akimoto S, Shimazaki J. Effect of naftopidil on urethral obstruction in benign prostatic hyperplasia: assessment by urodynamic studies. Prostate 1994; 25: 46-52.
3. Yamanishi T, Yasuda K, Tojo M, Hattori T, Sakakibara R, Shimazaki J. Improvement of urethral resistance after the administration of an alpha-adrenoceptor blocking agent, urapidil, for neuropathic voiding dysfunction. Paraplegia 1994; 32: 271-6.
4. Akiyama K, Noto H, Nishizawa O et al. Effect of KMD-3213, an alpha 1A-adrenoceptor antagonist, on the prostatic urethral pressure and blood pressure in male decerebrate dogs. Int. J. Urol. 2001; 8: 177-83.
5. Tanaka Y, Masumori N, Itoh N et al. Urodynamic effects of terazosin treatment for Japanese patients with symptomatic benign prostatic hyperplasia. J. Urol. 2002; 167: 2492-5.
6. Witte DG, Brune ME, Katwala SP et al. Modeling of relationships between pharmacokinetics and blockade of agonist-induced elevation of intraurethral pressure and mean arterial pressure in conscious dogs treated with alpha(1)-adrenoceptor antagonists. J. Pharmacol. Exp. Ther. 2002; 300: 495-504.
7. Wilt TJ, MacDonald R, Nelson D. Tamsulosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects. J. Urol. 2002; 167: 177-83.
8. Achari R, Hosmane B, Bonacci E, O'Dea R. The relationship between terazosin dose and blood pressure response in hypertensive patients. J. Clin. Pharmacol. 2000; 40: 1166-72.
9. Cushman WC, Materson BJ, Williams DW, Reda DJ. Pulse pressure changes with six classes of antihypertensive agents in a randomized, controlled trial. Hypertension 2001; 38: 953-7.
10. Alijotas-Reig J, Bove-Farre I, de Cabo-Frances F, Angles-Coll R. Effectiveness and safety of prehospital urapidil for hypertensive emergencies. Am. J. Emerg. Med. 2001; 19: 130-3.
11. Sugaya K, Nishijima S, Oda M, Morozumi M, Hatano T, Ogawa Y. Biochemical analysis of nocturia in the elderly. Neurourol. Urodyn. 2001; 20: 458-60.
12. Kadekawa K, Sugaya K, Ikehara A et al. Effects of terazosin on micturition disorders, blood pressure and plasma lipid level in patients with benign prostatic hypertrophy. Jpn J. Urol. Surg. 2002; 15: 111-8.
13. Sugaya K, Nishijima S, Miyazato M, Ashitomi K, Hatano T, Ogawa Y. Effects of intrathecal injection of tamsulosin and naftopidil, alpha-1A and -1D adrenergic receptor antagonists, on bladder activity in rats. Neurosci. Lett. 2002; 328: 74-6.
14. Sugaya K, Nishijima S. Effects of intrathecal injection of naftopidil on micturition reflex in rats with or without spinal cord injury. Jpn. Med. Soc. Paraplegia 2002; 15: 192-3.
15. Nieuwenhuys R. Survey of chemically defined cell groups and pathways. In: Nieuwenhuys R (ed.) Chemoarchitecture of the Brain. Springer-Verlag, Berlin, 1985, 7-113.
16. Binggeli C, Corti R, Sudano I, Luscher TF, Noll G. Effects of chronic calcium channel blockade on sympathetic nerve activity in hypertension. Hypertension 2002; 39: 892-6.
17. Esler M, Rumantir M, Kaye D et al. Sympathetic nerve biology in essential hypertension. Clin. Exp. Pharmacol. Physiol. 2001; 28: 986-9.
18. Leoncini G, Martinoli C, Viazzi F et al. Changes in renal resistive index and urinary albumin excretion in hypertensive patients under long-term treatment with lisinopril or nifedipine GITS. Nephron. 2002; 90: 169-73.
19. Shimizu Y, Itoh T, Hougaku H et al. Clinical usefulness of duplex ultrasonography for the assessment of renal arteriosclerosis in essential hypertensive patients. Hypertens. Res. 2001; 24: 13-7.
20. Stone EA, Zhang Y, Rosengarten H, Yeretsian J, Quartermain D. Brain alpha 1-adrenergic neurotransmission is necessary for behavioral activation to environmental change in mice. Neuroscience 1999; 94: 1245-52.
21. Rouquier L, Claustre Y, Benavides J. Alpha 1-adrenoceptor antagonists differentially control serotonin release in the hippocampus and striatum: a microdialysis study. Eur. J. Pharmacol. 1994; 261: 59-64.